| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Mitogen-activated protein kinase 9 |
|---|
| Ligand | BDBM50314071 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_627165 (CHEMBL1111807) |
|---|
| Kd | 2600±n/a nM |
|---|
| Citation |  Goldstein, DM; Kuglstatter, A; Lou, Y; Soth, MJ Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem53:2345-53 (2010) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Mitogen-activated protein kinase 9 |
|---|
| Name: | Mitogen-activated protein kinase 9 |
|---|
| Synonyms: | JNK-55 | JNK2 | JNK2/JNK3 | MAPK9 | MK09_HUMAN | Mitogen-Activated Protein Kinase 9 (JNK2) | Mitogen-activated protein kinase 8/9 | PRKM9 | SAPK1A | Stress-activated protein kinase JNK2 | c-Jun N-terminal kinase 2 | c-Jun N-terminal kinase 2 (JNK2) |
|---|
| Type: | Enzyme |
|---|
| Mol. Mass.: | 48131.49 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | JNK-2 was purchased from Upstate Cell Signaling Solutions (formerly Upstate Biotechnology). |
|---|
| Residue: | 424 |
|---|
| Sequence: | MSDSKCDSQFYSVQVADSTFTVLKRYQQLKPIGSGAQGIVCAAFDTVLGINVAVKKLSRP
FQNQTHAKRAYRELVLLKCVNHKNIISLLNVFTPQKTLEEFQDVYLVMELMDANLCQVIH
MELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTACTNF
MMTPYVVTRYYRAPEVILGMGYKENVDIWSVGCIMGELVKGCVIFQGTDHIDQWNKVIEQ
LGTPSAEFMKKLQPTVRNYVENRPKYPGIKFEELFPDWIFPSESERDKIKTSQARDLLSK
MLVIDPDKRISVDEALRHPYITVWYDPAEAEAPPPQIYDAQLEEREHAIEEWKELIYKEV
MDWEERSKNGVVKDQPSDAAVSSNATPSQSSSINDISSMSTEQTLASDTDSSLDASTGPL
EGCR
|
|
|
|---|
| BDBM50314071 |
|---|
| n/a |
|---|
| Name | BDBM50314071 |
|---|
| Synonyms: | 2-(2,4-difluorophenyl)-6-(1-(2,6-difluorophenyl)ureido)nicotinamide | CHEMBL1090090 | VX-702 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C19H12F4N4O2 |
|---|
| Mol. Mass. | 404.3178 |
|---|
| SMILES | NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F |
|---|
| Structure | 
|
|---|
Search and Browse
